Merck unlocks more value for investors

Article Excerpt

MERCK & CO. INC., $76.61 is a #1 Power Buy for your 2021 investing. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (; Shares o/s: 2.5 billion; Market cap: $191.7 billion; Divd. yield: 3.4%) completed the spinoff of its Organon & Co. (symbol OGN on New York) on June 3, 2021. That’s when it handed out the new shares to its investors. Organon aims to be a global healthcare company focused on improving the health of women. It will have a portfolio of more than 60 medicines targeting an entire spectrum of conditions that women face. As well, about 80% of the new company’s revenues will come from outside the U.S. The Chinese market, in particular, offers considerable potential. Merck & Co. is a #1 Power Buy for 2021. 2021…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.